ContraFect Corporation Company Profile
28 Wells Avenue
Yonkers NY 10701
914-207-2300
www.contrafect.com
Industry: Biotechnology
Sector: Healthcare

Description
ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company was founded in 2008 and is headquartered in Yonkers, New York.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.